Article Contents ::
- 1 The Brand Name ENEMAR Has Generic Salt :: Pancuronium
- 2 ENEMAR Is From Company Dolphin Priced :: Rs. 17.56
- 3 ENEMAR have Pancuronium is comes under Sub class Miscellaneous of Main Class Anti Infectives
- 4 Main Medicine Class:: Anti Infectives Sub Medicine Class :: Miscellaneous
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name ENEMAR Has Generic Salt :: Pancuronium
ENEMAR Is From Company Dolphin Priced :: Rs. 17.56
ENEMAR have Pancuronium is comes under Sub class Miscellaneous of Main Class Anti Infectives
Main Medicine Class:: Anti Infectives Sub Medicine Class :: Miscellaneous
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
|Brand Name||Company / Manufacturers||Strength||Unit||Price / 2ML|
|Company Brand Name||Salt Combination||Main Medical Class||Sub Medical Class|
|From Dolphin :: ENEMAR||Pancuronium||Anti Infectives||Miscellaneous|
Indications for Drugs ::
Adjunct to GA for Endotracheal intubation and to provide skeletal muscle ralaxation.
Drug Dose ::
Intravenous Facilitate endotracheal intubation Adult: Initially, 50-100 mcg/kg. Maintenance: 10-20 mcg/kg. Can be administered undiluted by rapid IV inj. Child: Neonate:30-40 mcg/kg. Maintenance: 10-20 mcg/kg 4-6 hrly as necessary. 1 mth-18 yr: initially 60-100 mcg/kg, then 10-20 mcg/kg repeated as recquired. Muscle relaxant in general anaesthesia Adult: Initially, 50-100 mcg/kg. Maintenance: 10-20 mcg/kg. Can be administered undiluted by rapid IV inj. Child: Neonate:30-40 mcg/kg. Maintenance: 10-20 mcg/kg 4-6 hrly as necessary. 1 mth-18 yr: initially 60-100 mcg/kg, then 10-20 mcg/kg repeated as recquired. Facilitate mechanical ventilation in intensive care Adult: 60 mcg/kg every 60-90 min. May be administered undiliuted by rapid IV inj. Renal impairment: CrCl (ml/min) 10-50 50% dose <10 avoid Hepatic impairment: Hepatic impairment may result in a slower onset of action, higher initial dosage and longer neuromuscular blockade. Contraindication ::
Anuria. Relatively contraindicated in conditions of reduced airway control. Lactation.
Drug Precautions ::
Myasthenia gravis; severe electrolyte disorders; severe CV disease; pregnancy. Hepatic and renal function impairment. Hypothermia; jaundice; hypermagnesaemia, hypocalcaemia, hypokalaemia, hypoproteinaemia, acidosis, alkalosis, hypercalcemia. In obese patients, dose should be based on ideal body wt. Elderly; previous anaphylactic reactions to other neuromuscular-blocking agents. Burn patients (>30% of body) may be resistant to action for 5-70 days after injury. Demyelinating lesions, peripheral neuropathies, denervation, infection, muscle trauma, and DM may antagonise the neuromuscular blockade effects of drug. Neuromuscular diseases, acute intermittent porphyria, Eaton-Lambert syndrome. Maintain adequate airway and respiratory support during use.
Drug Side Effects ::
Tachycardia may occur due to vagal blockade and especially during light anaesthesia. May decrease intra-ocular pressure and induce miosis; excessive salivation; transient rashes and itching; wheezing; elevation in pulse rate, BP, cardiac output; erythema; burning sensation along vein; profound muscle weakness; bronchospasm; hypersensitivity reaction; acute quadriplegic myopathy syndrome, myositis ossificans. Potentially Fatal: Rare anaphylactoid reactions; bradycardia, bronchospasm, hypotension and CV collapse; respiratory depression.
Pregnancy category ::
Drug Mode of Action ::
Pancuronium bromide is a non-depolarising neuromuscular blocking agent with curarimimetic action through competitive blockade at the myoneural junction by binding with cholinergic receptor sites.
Drug Interactions ::
Neuroleptanalgaesia may decrease neuromuscular activity. Action may be prolonged and/or potentiated by aminoglycoside antibiotics, lithium, diazepam, lidocaine (high dose), quinidine, tetracyclines, propranolol, thiamine (high dose), parenteral magnesium sulphate, MAOIs, quinine, protamine, carbamazepine, donepezil and phenytoin (if pancuronium is given concurrently for <1 wk). Action may be decreased by neostigmine, edrophonium, high-dose or long term corticosteroids, adrenaline (may also potentiate effect), azathioprine, theophylline (high doses), clindamycin, nifedipine, piperacillin, polymixins, verapamil, procainamide. Furosemide may increase or decrease effects. TCAs may increase risk of arrhythmias and hypotension during anaesthesia. Potentially Fatal: Potentiated by volatile anaesthetics (isoflurane and enflurane) and local anaesthetics. Prior admin of suxamethonium can increase the intensity of neuromuscular block. Concomitant use with digoxin may increase risk of serious cardiac arrhythmias.